CD63 is a 53 kDa lysosomal membrane glycoprotein that has been identified as a platelet activation molecule that belongs to the tetraspanin family, which is characterized by the presence of four hydrophobic domains. The tetraspanin CD63 (also known as LAMP-3, melanoma associated antigen ME491, TSPAN30, MLA1 and OMA81H) is a lysosomal membrane glycoprotein that translocates to the plasma membrane after platelet activation. CD63 is expressed on activated platelets, monocytes and macrophages and is weakly expressed on granulocytes, T cell and B cells. It is also strongly expressed in early melanoma, breast carcinoma, merker cell carcinoma, astrocytoma and lung adenocarcinoma. Recent reports also indicate that CD63 is a good prognostic biomarker for human astrocytomas and earlier stages of lung carcinoma. Additionally, CD63 has been useful in differentiating renal oncocytomas (RO) from eosinophilic variants of chromophobe renal cell carcinoma (RCCs). CD63 deficiency is associated with Hermansky-Pudlak syndrome.
|Tissue Type/Cancer Type|
0.5 mL – Manual – Concentrate, 1 mL – Manual – Concentrate, 6 mL – Manual – RTU, 50 Tests – Automation – Xmatrx, 100 Tests – Automation – i6000, 200 Tests – Automation – Xmatrx, 5 slides – Xmatrx, 5 slides – Manual